Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
<h4>Background</h4>Preclinical data support further investigation of ascorbic acid in pancreatic cancer. There are currently insufficient safety data in human subjects, particularly when ascorbic acid is combined with chemotherapy.<h4>Methods and findings</h4>14 subjects with...
Enregistré dans:
Auteurs principaux: | Daniel A Monti, Edith Mitchell, Anthony J Bazzan, Susan Littman, George Zabrecky, Charles J Yeo, Madhaven V Pillai, Andrew B Newberg, Sandeep Deshmukh, Mark Levine |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2012
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/09b8615a61a7470da45dce0f0c6aad39 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Erlotinib in the treatment of advanced pancreatic cancer
par: Robin K Kelley, et autres
Publié: (2008) -
Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
par: Jasmine G Lee, et autres
Publié: (2012) -
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
par: Gong DJ, et autres
Publié: (2013) -
Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
par: Guo ZY, et autres
Publié: (2018) -
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
par: Ru Chen, et autres
Publié: (2017)